Piramal Pharma’s Lexington Facility Receives Four US FDA Observations After GMP Audit

has informed the market that the US Food and Drug Administration (FDA) conducted a Good Manufacturing Practices (GMP) inspection at its Lexington, Kentucky facility from 3 December to 10 December 2025, resulting in a Form-483 with four observations that primarily focus on procedural improvements rather than critical or systemic compliance failures, and are expected to be classified as Voluntary Action Indicated (VAI). The company has already initiated preparation of a detailed response to submit within the stipulated timelines and reaffirmed its commitment to high quality and regulatory standards, while emphasising proactive engagement with the regulator to address each point comprehensively and ensure continued adherence to global compliance expectations. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.